Review of Glypican-3-Targeted Imaging Agents for Hepatocellular Carcinoma.

IF 1.7 4区医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL

Cancer Biotherapy and Radiopharmaceuticals Pub Date : 2026-11-01 Epub Date: 2026-07-01 DOI:10.1177/10849785261458595

Wenye Li, Liqin Liu

{"title":"Review of Glypican-3-Targeted Imaging Agents for Hepatocellular Carcinoma.","authors":"Wenye Li, Liqin Liu","doi":"10.1177/10849785261458595","DOIUrl":null,"url":null,"abstract":"Background: Hepatocellular carcinoma (HCC) is a highly prevalent malignant tumor globally, with low survival rates in advanced stages. Therefore, early diagnosis and precision therapy are pivotal to improving patient prognosis. Glypican-3 (GPC3) acts as a specific molecular target for HCC, which is highly expressed in 70%-85% of HCC tissues but undetectable in normal liver tissues, hepatitis, liver cirrhosis, and other pathological conditions. This stringent expression regulation renders it an ideal tumor-specific target.Main content: Based on the biological properties of GPC3, various specific tumor imaging agents have been developed, covering multiple biomolecular types, including antibodies, peptides, and aptamers. This review systematically summarizes the research advances, application advantages, and existing challenges of three types of molecular imaging probes in the precise diagnosis and treatment of HCC. It focuses on the development strategies of these probes and evaluates their current limitations in light of key characterization parameters.Conclusion: This review aims to provide new research ideas for the precision diagnosis of HCC and promote the translation of clinical applications.","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":"773-781"},"PeriodicalIF":1.7000,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Biotherapy and Radiopharmaceuticals","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/10849785261458595","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/7/1 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Hepatocellular carcinoma (HCC) is a highly prevalent malignant tumor globally, with low survival rates in advanced stages. Therefore, early diagnosis and precision therapy are pivotal to improving patient prognosis. Glypican-3 (GPC3) acts as a specific molecular target for HCC, which is highly expressed in 70%-85% of HCC tissues but undetectable in normal liver tissues, hepatitis, liver cirrhosis, and other pathological conditions. This stringent expression regulation renders it an ideal tumor-specific target.

Main content: Based on the biological properties of GPC3, various specific tumor imaging agents have been developed, covering multiple biomolecular types, including antibodies, peptides, and aptamers. This review systematically summarizes the research advances, application advantages, and existing challenges of three types of molecular imaging probes in the precise diagnosis and treatment of HCC. It focuses on the development strategies of these probes and evaluates their current limitations in light of key characterization parameters.

Conclusion: This review aims to provide new research ideas for the precision diagnosis of HCC and promote the translation of clinical applications.

查看原文本刊更多论文

glypican -3靶向肝细胞癌显像剂的研究进展。

背景：肝细胞癌（HCC）是一种全球高度流行的恶性肿瘤，晚期生存率较低。因此，早期诊断和精准治疗是改善患者预后的关键。Glypican-3 （GPC3）是HCC的特异性分子靶点，在70%-85%的HCC组织中高表达，但在正常肝组织、肝炎、肝硬化等病理条件下检测不到。这种严格的表达调控使其成为理想的肿瘤特异性靶点。主要内容：基于GPC3的生物学特性，已开发出多种特异性肿瘤显像剂，涵盖多种生物分子类型，包括抗体、多肽、适体等。本文系统总结了三种分子成像探针在HCC精准诊断和治疗中的研究进展、应用优势及存在的挑战。重点介绍了这些探针的开发策略，并根据关键表征参数评估了它们目前的局限性。结论：本综述旨在为HCC的精确诊断提供新的研究思路，促进临床应用的转化。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Biotherapy and Radiopharmaceuticals 医学-核医学

CiteScore

7.80

自引率

2.90%

发文量

审稿时长

3 months

期刊介绍： Cancer Biotherapy and Radiopharmaceuticals is the established peer-reviewed journal, with over 25 years of cutting-edge content on innovative therapeutic investigations to ultimately improve cancer management. It is the only journal with the specific focus of cancer biotherapy and is inclusive of monoclonal antibodies, cytokine therapy, cancer gene therapy, cell-based therapies, and other forms of immunotherapies. The Journal includes extensive reporting on advancements in radioimmunotherapy, and the use of radiopharmaceuticals and radiolabeled peptides for the development of new cancer treatments.